Hanne Verswyvel

Chapter 1 │ Page 27 37. Walsh, R.J., R. Sundar, and J.S.J. Lim, Immune checkpoint inhibitor combinations - current and emerging strategies. British Journal of Cancer, 2023. 128(8): p. 14151417. 38. Borgeaud, M., et al., Novel targets for immune-checkpoint inhibition in cancer. Cancer Treatment Reviews, 2023. 120: p. 102614. 39. Long, G.V., et al., Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evidence, 2023. 2(4): p. EVIDoa2200239. 40. Nishizaki, D., et al., Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. ESMO Open, 2024. 9(4): p. 102942. 41. Dhatchinamoorthy, K., J.D. Colbert, and K.L. Rock, Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol, 2021. 12: p. 636568. 42. Chen, S., H. Zhu, and Y. Jounaidi, Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduction and Targeted Therapy, 2024. 9(1): p. 302. 43. Zhang, Q., et al., Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nature Immunology, 2018. 19(7): p. 723-732. 44. Neo, S.Y., et al., CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest, 2020. 130(3): p. 1185-1198. 45. Böttcher, J.P., et al., NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell, 2018. 172(5): p. 10221037.e14. 46. Schuster, I.S., et al., “Natural Regulators”: NK Cells as Modulators of T Cell Immunity. Frontiers in Immunology, 2016. 7. 47. Kepp, O., L. Zitvogel, and G. Kroemer, Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade. OncoImmunology, 2019. 8(10): p. e1637188. 48. Asadzadeh, Z., et al., Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers (Basel), 2020. 12(4). 49. Jiao, Y., F. Cao, and H. Liu, Radiation-induced Cell Death and Its Mechanisms. Health Phys, 2022. 123(5): p. 376-386. 50. van Schaik, T.A., K.S. Chen, and K. Shah, Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Front Oncol, 2021. 11: p. 678562. 51. Fucikova, J., et al., Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death & Disease, 2020. 11(11): p. 1013. 52. Martins, I., et al., Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death & Di erentiation, 2014. 21(1): p. 79-91. 53. Obeid, M., et al., Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine, 2007. 13(1): p. 54-61. 54. Cao, S.S. and R.J. Kaufman, Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal, 2014. 21(3): p. 396413. 55. Perillo, B., et al., ROS in cancer therapy: the bright side of the moon. Experimental & Molecular Medicine, 2020. 52(2): p. 192-203.

RkJQdWJsaXNoZXIy MTk4NDMw